Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...

US stocks were largely lower on Wednesday as investors digested a hotter-than-expected January inflation reading and ...

As President Trump threatens a wider trade war on EU and other allies, an obscure global tax battle could be one retaliatory ...

The Biomarkers Market is expected to grow from USD 79.3 billion in 2023-e to USD 187.4 billion by 2030, at a CAGR of 14.7% ...

The S&P 500's ( ^GSPC )' record run could face a setback, according to JPMorgan Market Intelligence. The team estimates the ...

Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (" Hyperscale Data ” or the " Company ”), today announced that it has successfully paid 32 consecutive monthly cash dividends ...